Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Propulsid Physician Education On Cardiac Risk To Be Presented To Committee

Executive Summary

Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.

You may also be interested in...



Propulsid Limited Access Program Allows Off-Label Use To Continue

FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.

Propulsid Limited Access Program Allows Off-Label Use To Continue

FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.

J&J, Lilly & Merck Reassure Investors About Medicare Reform Process

The lessons from the health care reform debate in the mid-1990s will ensure a more "sensible" debate over health care in 2000, J&J CEO Ralph Larsen told analysts during a Jan. 25 conference call.

Related Content

UsernamePublicRestriction

Register

PS035530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel